Dernières nouvelles pour Celanese (NYSE:CE) Stock

Celanese

Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.

Celanese Corp

CE Energy Acquisition Corp.

CEA Industries Inc

Creations Inc

CEA Space Partners I Corp.

CENTRAL AUTOMOTIVE PRODS by Central Automotive Products Ltd.

Central Automotive Products Ltd

China Eastern Airlines Corp Ltd ADR

CHINA EVERBRIGHT BANK ORD by China Everbright Bank Co Ltd.

China Everbright Bank Co Ltd

CITYCHAMP WATCH & JEWELLE by Citychamp Watch & Jewellery Group Ltd.

Citychamp Watch & Jewellery Group Ltd

Cebu Air Inc

CANASIA ENERGY CORP by CANASIA ENERGY CORP.

CanAsia Energy Corp

Saltbae Capital Corp

Cecil Bancorp Inc

CECO Environmental Corp

Cedarlake Acquisition Corp

The Central and Eastern Europe Fund, Inc. (The) Common Stock

CENTRAL & EASTERN EUROPE FUND, INC.

Ceres Inc

CEEK VR

UpSnap Inc

Sprott Physical Gold and Silver Trust Units

Sprott Physical Gold and Silver Trust

Global X S&P Catholic Values Developed ex-U.S. ETF

CENTRAL FLA ST BK BELLEVW by Central Florida State Bank (Belleview FL)

COMML NATL FINCL CRP MICH by Commercial National Financial Corp (MI)

Commercial National Financial Corp (MI)

ETRACS Monthly Pay 1.5X Leveraged Closed-End Fund Index ETN

Saba Closed-End Funds ETF

Constellation Energy Corporation - Common Stock

Constellation Energy Corp

CHINA ED GROUP HLDGS LTD by CHINA ED GROUP HLDGS LTD.

China Education Group Holdings Ltd

CERRO GRANDE MINING CORP by Cerro Grande Mining Corp.

Cerro Grande Mining Corp

COSMO ENERGY HLDGS CO LTD by Cosmo Energy Hldgs Co Ltd

Cosmo Energy Holdings Co Ltd

Camber Energy Inc OM PAR $0.001 2022 NEW

COMPAL ELECTRONIC 144A GDR REP 5 ORD

COELACANTH ENERGY INC by COELACANTH ENERGY INC

Coelacanth Energy Inc

Camber Energy Inc

COMPAL USD DR

CONSOL Energy Inc

CONSOL ENERGY ORD

Cresco Ltd

Celsius - United States Dollar

Celcuity Inc

Bristol-Myers Squibb Company Celegne Contingent Value Rights

Celsius Holdings Inc

CELLCOM ISRAEL LTD ORD by Cellcom Israel, Ltd.

Cellcom Israel Ltd

Cellframe

Celo - United States Dollar

Celer Network - United States Dollar

Centamin PLC

CENTAMIN ORD

Celularity Inc

PREFERRED COMMERCE INC by Preferred Commerce Inc.

Preferred Commerce Inc

Celexpress Inc

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Technology Holdings Inc

ClearBridge MLP & Midstream Fund Inc Com (New)

ISHRS MSCI EM ASIA UCITS USD ETF

iShares J.P. Morgan EM Corporate Bond ETF

ISHRS MSCI EM CNSMR GRWTH USD ETF

CEN Biotech Inc

Caravan Energy Corp Ordinary Shares

CareNet Inc

Cenntro Inc

CENNZnet

Central Garden & Pet Company - Common Stock

Central Garden & Pet Co

Central Garden & Pet Company - Class A Common Stock Nonvoting

Century Aluminum Co

CENTURY ALUMINUM ORD

CEO America Inc

CeCors Inc

Cantor Equity Partners, Inc. - Class A ordinary shares

Cantor Equity Partners Inc

Cantor Equity Partners I Inc

Cantor Equity Partners I, Inc

CEPS PLC

Central Puerto S.A. American Depositary Shares (each represents ten Common Shares)

Central Puerto SA

Crestwood Equity Partners LP Unit Ltd Partnership Int (New)

CERES INC OM NEW

Cere Network

CERES GLOBAL AG CORP ORD by Ceres Global Ag Corp.

Ceres Global Ag Corp

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Holdings Inc

CERo Therapeutics Holdings, Inc. - Warrants

Cerus Corp

Certara Inc

COLOMBIA ENERGY RESOUR by Colombia Energy Resources, Inc.

Colombia Energy Resources Inc

SPDR Series Trust SPDR Bloomberg Enhanced Roll Yield Commodity Strategy No K-1 ETF

CES ENERGY SOLUTIONS ORD by CES Energy Solutions Corp.

CES Energy Solutions Corp

Deutsche Bank analyst David Begleiter upgraded Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) to Buy from Hold, lowering the price forecast to $110 from $135.
Celanese reported third-quarter adjusted earnings per share of $2.44, missing analyst estimates of $2.85. The company reported sales of $2.65 billion, missing analyst estimates of $2.7 billion, according to&nbsp;<a target="_blank" href="http://pro.benzinga.com/" rel="noreferrer noopener">Benzinga Pro</a>.
The analyst wasn&#8217;t surprised by Celanese missing third-quarter earnings and lowering fourth-quarter guidance.
For Begleiter, the shortfalls were due to weak demand in automotive, industrial and construction markets, which impacted many chemical companies this earnings season.
Particularly, the 57% fourth-quarter guidance shortfall surprised the analyst, but it was mainly due to temporary facility shutdowns to cut costs and reduce inventory.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41780680/super-micro-analysts-need-more-clarity-on-auditor-resignation-await-10-k-filing-man" rel="noreferrer noopener">Super Micro Analysts Need More Clarity On Auditor Resignation, Await 10-K Filing: &#8216;Management Did Not Address These Topics&#8217;</a>
Celanese likely misjudged the auto market, overproducing in the third quarter and creating excess inventory.
Begleiter added this won&#8217;t affect the company&#8217;s long-term earnings potential.
The analyst noted the 95% dividend cut should have happened two years ago when Celanese acquired DuPont&#8217;s Mobility &amp; Materials business for $11 billion.
Now, two years post-acquisition, Celanese is 5x leveraged (4.9x net debt to LTM EBITDA), leaving little margin for error.
The analyst suggested Celanese has strong operating leverage for a recovery, forecasting its EPS will rise from $10.50 in 2025 to over $14.50 by 2026, driven by factors such as interest rate cuts in Western countries, fiscal and monetary stimulus in China and several years of low industrial activity.
CE Price Action: Celanese shares are trading higher by 1.03% to $91.94 at publication Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41778433/s-p-500-dow-hit-record-highs-after-trump-win-fear-index-drops-20" target="_blank" rel="noreferrer noopener">S&amp;P 500, Dow Hit Record Highs After Trump Win; Fear Index Drops 20%</a></li>
</ul>

Equities

News

Markets

Analyst Ratings

Movers

Trading Ideas

General

Deutsche Bank Upgrades Celanese Stock: Analyst Highlights Strong Leverage, Long-Term Growth

Barclays analyst Michael Leithead maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Equal-Weight and lowers the price target from $151 to $101.

Price Target

Barclays Maintains Equal-Weight on Celanese, Lowers Price Target to $101

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/580f253b846faa000139ba71/robert-moskow">TD Cowen analyst Robert Moskow</a> upgraded the rating for The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) from Sell to Hold and raises the price target from $155 to $170. Clorox shares closed at $162.42 on Tuesday. <a href="https://www.benzinga.com/quote/CLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Trevor Young upgraded Revolve Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVLV#NYSE">RVLV</a>) from Underweight to Equal-Weight and raised the price target from $17 to $25. Revolve shares closed at $26.02 on Tuesday. <a href="https://www.benzinga.com/quote/RVLV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/616e99feb650db000151570b/rick-bienkowski">Leerink Partners analyst Rick Bienkowski</a> upgraded the rating for Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) from Market Perform to Outperform and increased the price target from $27 to $39. Beam Therapeutics shares closed at $23.93 on Tuesday. <a href="https://www.benzinga.com/quote/BEAM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst David Begleiter upgraded Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Hold to Buy and lowered the price target from $135 to $110. Celanese shares closed at $91.00 on Tuesday. <a href="https://www.benzinga.com/quote/CE/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>

Considering buying CLX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="547" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-1024x547.png" alt="" class="wp-image-632747" style="width:636px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-1024x547.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-768x410.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49.png 1230w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>

Upgrades

Pre-Market Outlook

BEAM

RVLV

This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday

Baird analyst Ghansham Panjabi maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Outperform and lowers the price target from $150 to $110.

Baird Maintains Outperform on Celanese, Lowers Price Target to $110

Morgan Stanley analyst Vincent Andrews maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Equal-Weight and lowers the price target from $140 to $100.

Morgan Stanley Maintains Equal-Weight on Celanese, Lowers Price Target to $100

Deutsche Bank analyst David Begleiter upgrades Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Hold to Buy and lowers the price target from $135 to $110.

Deutsche Bank Upgrades Celanese to Buy, Lowers Price Target to $110

Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) shares are tumbling on Tuesday after the company reported worse-than-expected third-quarter financial results and announced it intends to temporarily reduce its <a href="https://www.benzinga.com//node/41728472">quarterly dividend</a>.
What Happened: Celanese reported third-quarter adjusted earnings per share of $2.44, missing analyst estimates of $2.85. The company reported sales of $2.65 billion, missing analyst estimates of $2.7 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Celanese reported adjusted EBIT of $457 million, operating EBITDA of $644 million and operating profit of $248 million.
The company stated in its earnings release that it has implemented multiple measures to address challenges in the demand environment. Notably, it plans to reduce its quarterly dividend by approximately 95%, starting in the first quarter of 2025.
&#8220;In the third quarter, we faced a severely constrained demand environment that, in some cases like auto, degraded swiftly. I want to thank our teams for executing our value enhancing initiatives that are delivering improvements today while also laying the foundation for future growth,&#8221; said Lori Ryerkerk, chair and CEO of Celanese.
&#8220;Still, these actions have been increasingly offset in the current environment and the earnings generated fell short of our expectations. In response we are taking additional measures to navigate current challenges while positioning Celanese for long-term success. We are confident these actions will accelerate our growth and enhance long-term value.&#8221;
Related Link: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41732827/messi-of-ai-wall-street-analyst-gushes-over-robust-earnings-from-palantir">&#8216;Messi Of AI&#8217;: Wall Street Analyst Gushes Over &#8216;Robust&#8217; Earnings From Palantir</a>
Celanese said it reduced its manufacturing costs by temporarily halting production at select facilities worldwide. The company anticipates a $200 million boost in cash flow from inventory reductions in the fourth quarter. Celanese noted that it&#8217;s targeting over $75 million in savings by the end of 2025.
Following the company&#8217;s earnings report, Wells Fargo analyst Michael Sison downgraded Celanese from an <a href="https://www.benzinga.com/analyst-stock-ratings">Overweight rating</a> to an Equal-Weight rating and lowered the price target from $165 to $115. Mizuho analyst Kieran De Brun maintained a Neutral rating and lowered the price target from $132 to $120.
CE Price Action: At the time of publication, Celanese shares are down 24.7%, trading at $93.15, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: 777546 from Pixabay

Earnings

What's Going On With Celanese Stock Tuesday?

Mizuho analyst Kieran De Brun maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Neutral and lowers the price target from $132 to $120.

Mizuho Maintains Neutral on Celanese, Lowers Price Target to $120

U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Tuesday.
Shares of Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) fell sharply in today's pre-market trading after the company reported worse-than-expected third-quarter financial results and announced it intends to temporarily reduce its quarterly dividend.
Celanese reported quarterly earnings of $2.44 per share which missed the analyst consensus estimate of $2.85 per share. The company reported quarterly sales of $2.65 billion which missed the analyst consensus estimate of $2.70 billion.
Celanese shares dipped 15.8% to $103.89 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) shares fell 19.4% to $2.10 in pre-market trading after the company reported weak third-quarter sales.</li>
<li>JELD-WEN Holding, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JELD#NYSE">JELD</a>) shares declined 18.5% to $11.51 in pre-market trading after the company reported downbeat quarterly results and lowered FY24 sales forecast.</li>
<li>Lattice Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) declined 18% to $42.55 in pre-market trading following soft fourth-quarter guidance.</li>
<li>Altice USA, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATUS#NYSE">ATUS</a>) fell 14.3% to $2.22 in pre-market trading after the company reported weak third-quarter financial results.</li>
<li>MediaAlpha, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAX#NYSE">MAX</a>) declined 13% to $13.99 in pre-market trading.</li>
<li>Tactile Systems Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) fell 10.3% to $13.55 in pre-market trading after the company posted weak quarterly sales and lowered FY24 sales forecast.</li>
<li>Cirrus Logic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRUS#NASDAQ">CRUS</a>) shares fell 9.7% to $99.83 in pre-market trading following second-quarter results.</li>
<li>Apellis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) dipped 9.5% to $25.84 in pre-market trading following weak quarterly results.</li>
<li>Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) shares fell 6.5% to $12.26 in pre-market trading following downbeat third-quarter results.</li>
<li>Teradata Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>) shares declined 5.6% to $31.51 in pre-market trading after reporting third-quarter results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41740698/top-3-health-care-stocks-youll-regret-missing-in-november">Top 3 Health Care Stocks You&#8217;ll Regret Missing In November</a></li>
</ul>

APLS

ATUS

CRUS

JELD

LSCC

NVTS

TCMD

Celanese Posts Downbeat Results, Joins Cirrus Logic, Teradata And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Canaccord Genuity raised Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) price target from $24 to $28. Canaccord Genuity analyst Maria Ripps maintained a Buy rating. Hims &amp; Hers Health shares closed at $20.76 on Monday. See how other analysts view this stock.</li>
<li>Benchmark raised the price target for Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) from $440 to $450. Benchmark analyst Matthew Harrigan maintained a Buy rating. Charter Communications shares closed at $375.83 on Monday. <a href="https://www.benzinga.com/quote/CHTR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo cut the price target for Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from $165 to $115. Wells Fargo analyst Michael Sison downgraded the stock from Overweight to Equal-Weight. Celanese shares closed at $123.50 on Monday. <a href="https://www.benzinga.com/quote/CE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group slashed Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) price target from $95 to $75. Telsey Advisory Group analyst Joseph Feldman downgraded the stock from Outperform to Market Perform. Dollar Tree shares settled at $66.81 on Monday. <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Susquehanna slashed Lattice Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) price target from $65 to $55. Susquehanna analyst Christopher Rolland maintained a Positive rating. Lattice Semiconductor shares closed at $51.89 on Monday. <a href="https://www.benzinga.com/quote/LSCC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) price target from $7 to $5. Baird analyst Tristan Gerra maintained an Outperform rating. Navitas Semiconductor shares closed at $2.61 on Monday. <a href="https://www.benzinga.com/quote/NVTS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital increased the price target for Air Transport Services Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATSG#NASDAQ">ATSG</a>) from $22 to $22.5. Loop Capital analyst Rick Paterson downgraded the stock from Buy to Hold. Air Transport shares settled at $22.00 on Monday. <a href="https://www.benzinga.com/quote/ATSG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird cut Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) price target from $19 to $14. Baird analyst Eric Coldwell maintained a Neutral rating. Owens &amp; Minor shares closed at $12.00 on Monday. <a href="https://www.benzinga.com/quote/OMI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel boosted the price target for Alkermes plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) from $25 to $36. Stifel analyst Paul Matteis upgraded the stock from Hold to Buy. Alkermes shares closed at $26.59 on Monday. <a href="https://www.benzinga.com/quote/ALKS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities boosted MasTec, Inc.. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) price target from $133 to $173. Truist Securities analyst Jamie Cook upgraded the stock from Hold to Buy. MasTec shares closed at $132.61 on Monday. <a href="https://www.benzinga.com/quote/MTZ/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41740698/top-3-health-care-stocks-youll-regret-missing-in-november">Top 3 Health Care Stocks You&#8217;ll Regret Missing In November</a></li>
</ul>

ALKS

ATSG

CHTR

DLTR

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Charter Communications To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday

Wells Fargo analyst Michael Sison downgrades Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Overweight to Equal-Weight and lowers the price target from $165 to $115.

Downgrades

Wells Fargo Downgrades Celanese to Equal-Weight, Lowers Price Target to $115

WIIM

Celanese shares are trading lower after the company reported worse-than-expected Q3 financial results and announced it intends to temporarily reduce its quarterly dividend.

Shares of Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) rose sharply in today's pre-market trading after the company reported better-than-expected third-quarter financial results and issued guidance <a href="https://www.benzinga.com/news/earnings/24/11/41730179/palantir-q3-earnings-revenue-beat-eps-beat-customers-up-39-raises-guidance-results-driven-by-unrele">above consensus estimates</a>.
Revenue increased 5% year over year to $3.07 billion, beating the consensus of $3.05 billion. Adjusted EPS of 77 cents surpassed the street view of 68 cents.
Palantir Technologies shares rose 12.9% to $46.75 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Simpple Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPPL#NASDAQ">SPPL</a>) gained 69.5% to $2.00 in pre-market trading after jumping around 269% on Monday.</li>
<li>Bionomics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) rose 67.6% to $0.3219 in pre-market trading. Bionomics received milestone payment of AUS$1 million from Carina Biotech for BNC101 partnered legacy oncology program.</li>
<li>Avalon GloboCare Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALBT#NASDAQ">ALBT</a>) shares surged 42.4% to $3.19 in pre-market trading after dipping 24% on Monday.</li>
<li>QuinStreet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNST#NASDAQ">QNST</a>) climbed 29.8% to $26.22 in pre-market trading after the company posted upbeat quarterly results and raised its FY25 sales outlook.</li>
<li>Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) gained 26.1% to $87.83 in pre-market trading after the company announced better-than-expected quarterly results.</li>
<li>Zyversa Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares rose 15.3% to $2.10 in pre-market trading after falling 5% on Monday.</li>
<li>Vimeo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMEO#NASDAQ">VMEO</a>) gained 15.2% to $5.54 in pre-market trading after the company posted upbeat quarterly results.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) gained 12.6% to $3.12 in pre-market trading.</li>
<li>Alarum Technologies Ltd &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) gained 16.6% to $14.39 in pre-market trading.</li>
<li>Elevai Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) gained 11.9% to $0.0225 in pre-market trading after the company announced update and extension of pending offer to exchange.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Marqeta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) shares tumbled 38.8% to $3.64 in pre-market trading following weak quarterly sales.</li>
<li>Verrica Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) shares fell 31.4% to $0.98 in pre-market trading after the company posted downbeat quarterly results.</li>
<li>Trio Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPET#NYSE">TPET</a>) dipped 24.8% to $0.0960 in pre-market trading after the company announced a 1-for-20 reverse stock split.</li>
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) shares fell 19.4% to $2.10 in pre-market trading after the company reported weak third-quarter sales.</li>
<li>Lattice Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) declined 18% to $42.55 in pre-market trading following soft fourth-quarter guidance.</li>
<li>Nft Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MI#NYSE">MI</a>) shares dipped 16.1% to $7.50 in pre-market trading after gaining 9% on Monday.</li>
<li>Vast Renewables Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) fell 16.2% to $5.66 in pre-market trading after surging more than 40% on Monday.</li>
<li>Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) fell 15.8% to $103.89 in today's pre-market trading after the company reported worse-than-expected third-quarter financial results and announced it intends to temporarily reduce its quarterly dividend.</li>
<li>Altice USA, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATUS#NYSE">ATUS</a>) fell 14.3% to $2.22 in pre-market trading after the company reported weak third-quarter financial results.</li>
<li>Tactile Systems Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) fell 10.3% to $13.55 in pre-market trading after the company posted weak quarterly sales and lowered FY24 sales forecast.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41735761/dow-tumbles-250-points-as-investors-brace-for-high-stakes-presidential-election-greed-index-enters-">Dow Tumbles 250 Points As Investors Brace For High-Stakes Presidential Election: Greed Index Enters &#8216;Fear&#8217; Zone</a></li>
</ul>

ALAB

ALAR

ALBT

BNOX

ELAB

PLTR

QNST

SPPL

TPET

VMEO

VRCA

VSTE

ZVSA

Why Palantir Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

Celanese will continue to take actions commensurate with the current demand environment. To this end, the Company intends to temporarily reduce the quarterly dividend by approximately 95 percent beginning in the first quarter of 2025. This action is a prudent and cost-effective path forward to support deleveraging. In addition, Celanese is taking the following actions to drive continued improvement to earnings and cash generation:
<ul>
<li>Reducing manufacturing costs through the end of 2024 by temporarily idling production facilities in every region and driving cash generation through an expected $200 million inventory release in the fourth quarter.</li>
<li>Implementing additional cost reduction programs expected to realize incremental savings greater than $75 million by the end of 2025. The focus of the programs will be on driving productivity in selling, general, and administrative (SG&amp;A) costs.</li>
<li>Continuing to focus on efficiently and stringently deploying capital, and targeting next year's capex spending to be below 2024 levels.</li>
<li>Closing on a 364-day delayed draw prepayable term loan for up to $1 billion. The Company expects to draw on the term loan in the first quarter of 2025 for use towards the $1.3 billion maturing debt.</li>
</ul>

Guidance

Celanese Reducing Manufacturing Costs Through The End Of 2024 By Temporarily Idling Production Facilities In Every Region And Driving Cash Generation Through An Expected $200M Inventory Release In Q4. Implementing Additional Cost Reduction Programs Expected To Realize Incremental Savings Greater Than $75M By The End Of 2025.

Outlook
"We expect demand conditions to worsen in the fourth quarter, as automotive and industrial segments react to recent dynamics by seasonally destocking at heavier than normal levels. While we expect this destocking to be temporary and contained to the quarter, we will significantly slow our production to match this demand level and to generate cash through inventory draw. Based on these factors, we anticipate fourth quarter adjusted earnings per share of approximately $1.25," said Lori Ryerkerk. "We hold ourselves to a high standard at Celanese, and are taking additional actions to strengthen our company. Our focus is on driving business improvement through earnings growth, cost reductions, free cash flow expansion, and deleveraging to position Celanese for long-term shareholder value creation."
Reconciliations of forecasted non-GAAP measures such as adjusted earnings per share, adjusted EBIT or free cash flow to the equivalent U.S. GAAP measures (diluted earnings per share, net earnings (loss) attributable to Celanese Corporation and net cash provided by (used in) operations, respectively), are not available without unreasonable efforts because a forecast of Certain Items, such as mark-to-market pension gains/losses, and other items is not practical. For more information, see "Non-GAAP Financial Measures" below.
The Company's prepared remarks related to the third quarter will be posted on its website at investors.celanese.com under Financial Information/Financial Document Library on November 4, 2024. Information about Non-US GAAP measures is included in a Non-US GAAP Financial Measures and Supplemental Information document posted on our investor relations website under Financial Information/Non-GAAP Financial Measures. See also "Non-GAAP Financial Measures" below.
Celanese Corporation is a global leader in chemistry, producing specialty material solutions used across most major industries and consumer applications. Our businesses use our chemistry, technology and commercial expertise to create value for our customers, employees and shareholders. We support sustainability by responsibly managing the materials we create and growing our portfolio of sustainable products to meet customer and societal demand. We strive to make a positive impact in our communities and to foster inclusivity across our teams. Celanese Corporation is a Fortune 500 company that employs approximately 12,400 employees worldwide with 2023 net sales of $10.9 billion.

Celanese Says "We Expect Demand Conditions To Worsen In Q4, As Automotive And Industrial Segments React To Recent Dynamics By Seasonally Destocking At Heavier Than Normal Levels. While We Expect This Destocking To Be Temporary And Contained To The Quarter, We Will Significantly Slow Our Production To Match This Demand Level And To Generate Cash Through Inventory Draw. Based On These Factors, We Anticipate Q4 Adj EPS Of ~$1.25"

Dividends

Celanese Intends To Temporarily Reduce The Quarterly Dividend By ~95% Beginning In Q1 2025

Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) reported quarterly earnings of $2.44 per share which missed the analyst consensus estimate of $2.85 by 14.39 percent. This is a 2.4 percent decrease over earnings of $2.50 per share from the same period last year. The company reported quarterly sales of $2.65 billion which missed the analyst consensus estimate of $2.70 billion by 1.93 percent. This is a 2.75 percent decrease over sales of $2.72 billion the same period last year.

Earnings Misses

Celanese Q3 Adj $2.44 Misses $2.85 Estimate, Sales $2.65B Miss $2.70B Estimate

With U.S. stock futures trading mixed this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) to report quarterly earnings at $2.64 per share on revenue of $5.71 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Constellation Energy shares fell 5.5% to $243.99 in after-hours trading.</li>
<li>Analysts expect Marriott International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) to post quarterly earnings at $2.31 per share on revenue of $6.27 billion. The company will release earnings before the markets open. Marriott shares gained 0.5% to $261.75 in after-hours trading.</li>
<li>Chewy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) will replace Stericycle Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRCL#NASDAQ">SRCL</a>) in the S&amp;P MidCap 400 before the opening bell on Wednesday, Nov. 6. Waste Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) is acquiring Stericycle in a transaction expected to be completed soon. Chewy shares surged 5.1% to $28.51 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>After the markets close, Wynn Resorts, Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) is projected to report quarterly earnings at $1.01 per share on revenue of $1.73 billion. Wynn Resorts shares gained 0.2% to $95.87 in the after-hours trading session.</li>
<li>Analysts expect Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) to report quarterly earnings at $2.85 per share on revenue of $2.7 billion after the closing bell. Celanese shares gained 1.5% to $126.70 in after-hours trading.</li>
</ul>
Check This Out:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41685620/top-3-energy-stocks-that-are-preparing-to-pump-in-november">Top 3 Energy Stocks That Are Preparing To Pump In November</a></li>
</ul>
Photo courtesy: Shutterstock

CHWY

SRCL

WYNN

Marriott, Constellation Energy And 3 Stocks To Watch Heading Into Monday

Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $148.75, a high estimate of $178.00, and a low estimate of $128.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 10.09%. 
<img src="https://www.benzinga.com/files/images/story/2024/1730217656_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Celanese among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin McCarthy</td>
<td>Vertical Research</td>
<td>Announces</td>
<td>Sell</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$163.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$135.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$128.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$167.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$138.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$151.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$178.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ghansham Panjabi</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$130.00</td>
<td>$156.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Celanese. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Celanese compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Celanese's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Celanese's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Celanese analyst ratings.</a>
<h2>Discovering Celanese: A Closer Look</h2>
Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.
<h3>Understanding the Numbers: Celanese's Finances</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Celanese's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -5.15%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 5.85%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.18%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Celanese's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.6%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Celanese's debt-to-equity ratio surpasses industry norms, standing at 1.87. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Celanese's Future

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Dollar Tree downgraded, eBay upgraded: Wall Street's top analyst calls

Celanese (CE) is down -23.1%, or -$28.49 to $95.01. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial...

Celanese falls -23.1%

Celanese (CE) is down -24.9%, or -$30.70 to $92.80. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial...

Celanese falls -24.9%

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.&nbsp; 1. STOCK NEWS: Boeing's (BA) machinist union ha...

Boeing union to end strike, Palantir reports Q3 beat: Morning Buzz

Celanese Corporation (CE) Q3 2024 Earnings Call Transcript

Celanese ( ($CE) ) has released its Q3 earnings. Here is a breakdown of the information Celanese presented to its investors. Celanese Corporation i...

Comments

Celanese

Actualités

Dernières nouvelles pour Celanese (NYSE:CE) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL